What is the survival rate of Kymriah?
Studies are ongoing to monitor the survival rate of patients who received Kymriah (tisagenlecleucel) as a cancer treatment. Currently, the available data shows the survival rate is 87.7% for patients with relapsed or refractory follicular lymphoma at 24 months after the Kymriah infusion, and 43.6% for patients with aggressive B-cell non-Hodgkin’s lymphoma. The 5-year survival rate for patients with advanced B-cell acute lymphoblastic leukemia is 55%.
Children and young adults with advanced B-cell acute lymphoblastic leukemia (ALL)
The five-year overall survival rate in children and young adult patients with relapsed or refractory (r/r) B-cell acute lymphoblastic leukemia (ALL) is 55%. This means that 55% of patients treated with Kymriah were still alive after 5 years. This data is from the ELIANA clinical trial that included 79 patients.
Adults with relapsed or refractory diffuse large B-cell lymphoma
According to the Center for International Blood and Marrow Transplant Research CIBMTR, the 24-month overall survival rate was 43.6% out of 1159 patients receiving Kymriah for aggressive B-cell non-Hodgkin’s lymphoma. Another study reported a 12-month survival rate of 59%.
Adults with relapsed or refractory follicular lymphoma
In the ELARA study, the estimated 24-month progression-free survival was 57.4%. The overall survival was 87.7%. The ELARA study included 97 patients.
References
Awasthi, R., et. al. 2023. Kymriah® (tisagenlecleucel) – An overview of the clinical development journey of the first approved CAR-T therapy. In: Human Vaccines and Immunotherapeutics. DOI: https://doi.org/10.1080/21645515.2023.2210046
Dreyling, M., et. al. 2022. Long-Term Clinical Outcomes and Correlative Efficacy Analyses in Patients (Pts) with Relapsed/Refractory Follicular Lymphoma (r/r FL) Treated with Tisagenlecleucel in the Elara Trial. In: Blood. DOI: https://doi.org/10.1182/blood-2022-158024
Kymriah [package insert]. Updated June 2024. Novartis Pharmaceuticals Corporation. Accessed August 2, 2024 at https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aad3ba54-dfd3-4cb3-9e2b-c5ef89559189
Novartis. June 12, 2022. Novartis five-year Kymriah® data show durable remission and long-term survival maintained in children and young adults with advanced B-cell ALL. Accessed August 2, 2024 at https://www.novartis.com/news/media-releases/novartis-five-year-kymriah-data-show-durable-remission-and-long-term-survival-maintained-children-and-young-adults-advanced-b-cell-all
Read next
What's the difference between Kymriah and Yescarta?
Kymriah and Yescarta are two cell-based gene therapies. A few differences between the two medications include who and what they are FDA approved for, their dosage, and which companies make them. Continue reading
What is the cost of Kymriah?
Kymriah (tisagenlecleucel) is an expensive CAR-T cell cancer therapy costs over $612,000 for one treatment infusion, but most people do not pay this amount. In addition, the Centers for Medicare & Medicaid Services (CMS) states that CAR-T cell therapy would be covered for eligible people with Medicare. Continue reading
How is Kymriah administered?
Kymriah is administered as a suspension through a tube (intravenous catheter) into your vein. This single-dose infusion usually takes less than one hour. Continue reading
Related medical questions
- What type of drug is Kymriah (tisagenlecleucel)?
- What is the success rate of Rituxan (rituximab) in patients with blood cancers?
- What is the difference between Truxima and Rituxan?
- Does Truxima make you gain weight?
- What is the success rate of Breyanzi?
- What are the names of the BTK inhibitors?
- What is Zydelig used for and how does it work?
- What is the success rate of Epkinly?
- What is the difference between Rituxan and Rituxan Hycela?
- How is Rituxan Hycela administered?
- What type of drug is Copiktra?
- What type of drug is Yescarta (axicabtagene ciloleucel)?
- Prednisone: What are 12 Things You Should Know?
- What is the success rate of Monjuvi?
- What causes infusion reactions to rituximab?
- How does Monjuvi work?
- How is Monjuvi given / administered?
- What is glofitamab?
Drug information
- Kymriah Information for Consumers
- Kymriah prescribing info & package insert (for Health Professionals)
- Side Effects of Kymriah (detailed)
Related support groups
- Kymriah (5 questions, 3 members)
- Follicular Lymphoma (15 questions, 15 members)
- Diffuse Large B-Cell Lymphoma (14 questions, 3 members)
- B Cell Lymphoma (5 questions, 3 members)
- Acute Lymphoblastic Leukemia (22 questions, 15 members)